MYO7B

Across TCGA pan-cancer cohorts, MYO7B mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated MYO7B data layer compared with 18 for mass-spec protein and 12 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher MYO7B mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated MYO7B expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC and CCRCC are the cancer types where MYO7B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	II,III,IV	0.651	0.340	.002	21	view →
CCRCC	OS	Tertile	All	1.000	0.907	.023	2	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

MYO7B–PDAC (OS)

Open the PDAC breakdown →